• InflaRx announced publication of previously reported Phase 1 results for oral izicopan, supporting Phase 2 development in immune-inflammatory diseases.
• The study in 86 healthy participants found izicopan well tolerated across evaluated doses, with no serious adverse events.
• Treatment rapidly suppressed targeted inflammatory signaling, with sustained activity and drug exposure increasing with dose.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060730PRIMZONEFULLFEED9872118) on November 06, 2026, and is solely responsible for the information contained therein.